Document Detail


Microglia in gemistocytic astrocytomas.
MedLine Citation:
PMID:  17228265     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Although gemistocytic astrocytomas are graded as World Health Organization II astrocytomas, they behave more aggressively than other astrocytomas. Their proliferative potential is low, and it remains an intriguing question why these tumors are so biologically "successful." They show a high mutation rate of the P53 gene, cytological abnormalities, and frequent perivascular mononuclear infiltrates. Microglial cells, a feature of this astrocytoma variant, are of increasing interest in the context of glioma growth. METHODS: We selected 23 tumor biopsies from 201 samples obtained from patients with gemistocytic astrocytomas operated at Mayo Clinic between 1985 and 1998. These tumors were formerly analyzed for P53 mutations, p53 protein, and proliferative activity (). Immunolabeling for three microglial markers, including CR3/43, Ki-M1P, and iba1, was performed on adjacent tissue sections. In addition, in situ hybridization for the alpha-chain of the major histocompatibility complex (MHC) Class II molecule recognized by the CR3/43 monoclonal antibody was performed. RESULTS: A high number of microglia was detected in gemistocytic astrocytomas. More microglia were present if the fraction of gemistocytic tumor cells was high (correlation coefficient = 0.699; P < 0.0002). Interestingly, a number of gemistocytes were immunoreactive for MHC Class II molecules, an observation confirmed by in situ hybridization. Importantly, the higher the number of Class II immunoreactive gemistocytes, the fewer Class II positive microglial cells could be detected (correlation coefficient = -0.5649; P < 0.005). CONCLUSION: Our results support the view that gemistocytic astrocytomas contain unusually high numbers of microglial cells. We propose that the finding of aberrant MHC Class II expression by gemistocytic tumor cells correlates with a loss of immune-competent MHC Class II-expressing microglia. This may be related to the especially poor prognosis of gemistocytic astrocytomas for which induction of T cell anergy could provide one explanation.
Authors:
Fatemeh Geranmayeh; Bernd W Scheithauer; Christoph Spitzer; Fredric B Meyer; Ann-Cathrin Svensson-Engwall; Manuel B Graeber
Related Documents :
19934315 - Imatinib mesylate induces cisplatin hypersensitivity in bcr-abl+ cells by differential ...
20567995 - Action of sn 28049, a new dna binding topoisomerase ii-directed antitumour drug: compar...
12058275 - The farnesyltransferase inhibitor, fti-2153, inhibits bipolar spindle formation during ...
12151395 - Inactivation of p21waf1 sensitizes cells to apoptosis via an increase of both p14arf an...
9554825 - Positive biochemical effects of a bioartificial liver support system (balss) in a porci...
23049715 - Improved biolistic transfection of hair cells.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neurosurgery     Volume:  60     ISSN:  1524-4040     ISO Abbreviation:  Neurosurgery     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-01-17     Completed Date:  2007-03-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7802914     Medline TA:  Neurosurgery     Country:  United States    
Other Details:
Languages:  eng     Pagination:  159-66; discussion 166     Citation Subset:  IM    
Affiliation:
University Department of Neuropathology, Imperial College London, Faculty of Medicine, Division of Neuroscience and Mental Health, Hammersmith Hospitals Trust, London, England.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Astrocytoma / classification,  pathology*
Brain Neoplasms / classification,  pathology*
Female
Humans
Male
Microglia / pathology*
Middle Aged
Retrospective Studies

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genetic aberrations in gliomatosis cerebri.
Next Document:  Adenoviral-mediated gene transfer into the canine brain in vivo.